tiprankstipranks
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market
NAMS
NewAmsterdam Pharma Company
RESEARCH TOOLSreports
Want to see NAMS full AI Analyst Report?

NewAmsterdam Pharma Company (NAMS) Financial Statements

250 Followers

NewAmsterdam Pharma Company Financial Overview

NewAmsterdam Pharma Company's market cap is currently $3.47B. The company's EPS TTM is $-0.629; its P/E ratio is -19.69; NewAmsterdam Pharma Company is scheduled to report earnings on February 18, 2026, and the estimated EPS forecast is $-0.48. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Mar 23Dec 21
Income Statement
Total Revenue$ 22.50M$ 45.56M$ 14.09M$ 102.69M$ 0.00
Gross Profit$ 22.44M$ 45.56M$ 14.09M$ 102.69M$ 0.00
Operating Income$ -225.68M$ -176.29M$ -182.97M$ -3.56M$ -34.98M
EBITDA$ -242.32M$ -241.49M$ -176.86M$ -22.34M$ -41.37M
Net Income$ -203.82M$ -241.60M$ -176.94M$ -22.63M$ -41.78M
Balance Sheet
Cash & Short-Term Investments$ 636.24M$ 834.19M$ 340.45M$ 467.73M$ 60.38M
Total Assets$ 769.28M$ 864.62M$ 347.10M$ 478.50M$ 67.99M
Total Debt$ 202.00K$ 448.00K$ 60.00K$ 126.00K$ 186.51K
Net Debt$ -489.80M$ -771.29M$ -340.39M$ -467.60M$ -60.19M
Total Liabilities$ 85.85M$ 107.12M$ 58.70M$ 48.43M$ 11.36M
Stockholders' Equity$ 683.43M$ 757.50M$ 288.39M$ 430.07M$ 56.63M
Cash Flow
Free Cash Flow$ -148.03M$ -159.24M$ -141.24M$ 10.44M$ -29.54M
Operating Cash Flow$ -147.78M$ -158.56M$ -141.22M$ 10.66M$ -29.51M
Investing Cash Flow$ -174.92M$ -62.85M$ -24.00K$ -221.00K$ -24.00K
Financing Cash Flow$ 29.52M$ 659.51M$ 8.91M$ 391.90M$ 84.70M
Currency in USD

NewAmsterdam Pharma Company Earnings and Revenue History

Income Statement >

NewAmsterdam Pharma Company Debt to Assets

Balance Sheet >

NewAmsterdam Pharma Company Cash Flow

Cash Flow >

NewAmsterdam Pharma Company Forecast EPS vs Actual EPS

Earnings >